Showing 861-870 of 1784 results for "".
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/Engaging Your Patient: Shared Decision-Making in HF With Preserved Ejection FractionGDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin InhibitorsEvidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Brain Metastases Management: From Detection to Multidisciplinary Care
https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/How are SC immune checkpoint inhibitors changing care in solid tumors? Hear a physician–nurse interview and explore implications for your practice.Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
https://reachmd.com/programs/cme/optimize-outcomes-in-ckd-t2d-a-practical-approach-to-initiating-and-monitoring-combination-ns-mra-sglt2i-therapy/29904/Time is nephron mass! Learn how nephrologists apply CONFIDENCE data & 4-pillar therapy to transform CKD + T2D care in this real-world case.Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases
https://reachmd.com/programs/cme/decision-in-context-a-practical-framework-for-sequencing-systemic-and-cns-therapies-in-brain-metastases/54765/Apply clinical evidence on intracranial activity of systemic therapies to guide treatment sequencing and multidisciplinary care in brain metastases.The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
https://reachmd.com/programs/cme/the-hidden-threat-transforming-ckd-care-across-the-diabetes-spectrum/36523/Learn to identify hidden CKD risks in diabetes. Early diagnosis and new agents are reshaping T2D care today, with trials guiding future T1D treatment.